Key facts
- Notable investors include GSR United Capital, Haihe River Industry Fund, Tianjin Ringpu Bio-Technology Company.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Panru Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Panru Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Panru Biotechnology
Manufacturer of biotechnology innovations intended advance medical research, genetic diagnostics, and therapeutic development. The company offers expertise in mRNA vaccine technology, gene therapy methods, and biochemistry research capabilities, enabling healthcare institutions and pharmaceutical enterprises to enhance disease prevention and treatment outcomes.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Panru Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Panru Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Panru Biotechnology in its N-PORT filings yet. We sweep new filings monthly.